Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Has announcements × Lymphoma, B-Cell, Marginal Zone × zanubrutinib × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Leukemia, Lymphocytic, Chronic, B-Cell 2 Waldenstrom Macroglobulinemia 1 Recurrence 1 Lymphoma, Mantle-Cell 1 Lymphoma, Follicular 1 Lymphoma, B-Cell, Marginal Zone 1 B-cell Malignancies 1

Interventions

Rituximab 3 fludarabine 2 Lenalidomide 2 Cyclophosphamide 2 zanubrutinib 1 venetoclax 1 umbralisib 1 ublituximab 1 tafasitamab 1 pirtobrutinib 1 axicabtagene ciloleucel 1 Bendamustine Hydrochloride 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03846427 2024-10-26

MAGNOLIA

BeiGene

Phase 2 Completed

68 enrolled 28 charts 1 FDA

Lymphoma, B-Cell, Marginal Zone

Data powered by HemOnc (CC BY 4.0) Colophon ⚡